Theriva Biologics Statistics
Total Valuation
TOVX has a market cap or net worth of $9.15 million. The enterprise value is $4.39 million.
Important Dates
The last earnings date was Wednesday, November 12, 2025, before market open.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TOVX has 33.74 million shares outstanding. The number of shares has increased by 573.50% in one year.
| Current Share Class | 33.74M |
| Shares Outstanding | 33.74M |
| Shares Change (YoY) | +573.50% |
| Shares Change (QoQ) | +43.29% |
| Owned by Insiders (%) | 2.22% |
| Owned by Institutions (%) | 2.10% |
| Float | 32.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.41 |
| P/TBV Ratio | 1.36 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.90, with a Debt / Equity ratio of 0.41.
| Current Ratio | 0.90 |
| Quick Ratio | 0.84 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -166.95% and return on invested capital (ROIC) is -91.92%.
| Return on Equity (ROE) | -166.95% |
| Return on Assets (ROA) | -46.48% |
| Return on Invested Capital (ROIC) | -91.92% |
| Return on Capital Employed (ROCE) | -133.02% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.19M |
| Employee Count | 22 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -80.89% in the last 52 weeks. The beta is 0.34, so TOVX's price volatility has been lower than the market average.
| Beta (5Y) | 0.34 |
| 52-Week Price Change | -80.89% |
| 50-Day Moving Average | 0.38 |
| 200-Day Moving Average | 0.73 |
| Relative Strength Index (RSI) | 41.75 |
| Average Volume (20 Days) | 32,724,479 |
Short Selling Information
The latest short interest is 1.99 million, so 5.89% of the outstanding shares have been sold short.
| Short Interest | 1.99M |
| Short Previous Month | 239,896 |
| Short % of Shares Out | 5.89% |
| Short % of Float | 6.02% |
| Short Ratio (days to cover) | 0.05 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -26.38M |
| Pretax Income | -26.19M |
| Net Income | -26.19M |
| EBITDA | -26.27M |
| EBIT | -26.38M |
| Earnings Per Share (EPS) | -$4.74 |
Full Income StatementBalance Sheet
The company has $7.53 million in cash and $2.76 million in debt, giving a net cash position of $4.77 million or $0.14 per share.
| Cash & Cash Equivalents | 7.53M |
| Total Debt | 2.76M |
| Net Cash | 4.77M |
| Net Cash Per Share | $0.14 |
| Equity (Book Value) | 6.74M |
| Book Value Per Share | 0.65 |
| Working Capital | -1.10M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$18.48 million and capital expenditures -$35,000, giving a free cash flow of -$18.51 million.
| Operating Cash Flow | -18.48M |
| Capital Expenditures | -35,000 |
| Free Cash Flow | -18.51M |
| FCF Per Share | -$0.55 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
